Abstract
For many reasons, such as toxicity and lack of selectivity of photosensitisers, as well as complexity of technical procedures and inconstant therapeutic results, photodynamic therapy of highly recurrent superficial bladder cancer never gained wide acceptance in the urological community. However, the 25 years of experience combined with the recent discovery of new photosensitisers, such as protoporphyrin IX (PpIX) induced by 5-aminolevulinic acid (ALA) or ALA-derivatives or hypericin open new, very interesting perspectives in this therapeutic field.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Jichlinski, P., Leisinger, HJ. Photodynamic therapy in superficial bladder cancer: past, present and future. Urol Res 29, 396–405 (2001). https://doi.org/10.1007/s002400100215
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s002400100215